Actinogen files new patent applications
Filed with ASX · · 2 pages · English
• Actinogen has filed two new patent applications directed to: o a method of improving cognition or treating cognitive decline in cognitively healthy subjects o a commercial scale-up manufacturing process for Xanamem providing a novel, efficient synthesis methodology enabling direct access to high purity Xanamem • These patent applications further strengthen Actinogen’s IP portfolio, placing it in
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- FDA IND Update
- ACW to initiate XanaFX clinical trial in Fragile X syndrome
- R&D Tax Incentive Rebate received of A$2.9 million
- Offer Booklet
- Actinogen Presentation & Planned Conference Call
Later from Actinogen Medical
- Completion of Entitlement Offer
- FDA Grants ACW Rare Paediatric Disease Designation in FXS
- Resignation of Dr Bill Ketelbey as Chief Executive Officer
- ACW raises an addtional $3.55m under a Shortfall Placement
- Actinogen appoints Dr Steven Gourlay as CEO
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical